Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d’Ivo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Malar J
Asıl Yazarlar: Toure, Offianan A, Assi, Serge B, N’Guessan, Tiacoh L, Adji, Gbessi E, Ako, Aristide B, Brou, Marie J, Ehouman, Marie F, Gnamien, Laeticia A, Coulibaly, M’Lanhoro AA, Coulibaly, Baba, Beourou, Sylvain, Bassinka, Issiaka, Soumahoro, Adama, Kadjo, Florence, Tano, Mea A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2014
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251865/
https://ncbi.nlm.nih.gov/pubmed/25409546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-13-439
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller